Abstract
Human saliva quantitative monitoring of roxithromycin (ROX) at picomolar-level
by flow injection (FI) chemiluminescence (CL) analysis is described for the first
time, to our knowledge. Monitoring was based on the CL intensity from luminol-BSA
reaction, which can be quenched in the presence of ROX, with the decreasing CL
intensity linearly proportional to the logarithm of the ROX concentration, ranging
from 0.6 to 1000 pmol·L<sup>-1</sup>. The detection limit of the proposed method for
the determination of ROX was as low as 0.2 pmol·L<sup>-1</sup> (3?), and the
relative standard deviations were less than 4.0% (<i>n</i> = 7). A complete
analytical process, including sampling and washing for ROX determination, conducted
at a flow rate of 2.0 mL·min<sup>-1</sup>, was performed completely within 30 s,
yielding a sample efficiency of 120 h<sup>-1</sup>. The proposed method was
successfully applied to the determination of ROX in human saliva and serum samples
with recoveries from 90.9% to 110.1%. The continuous monitoring of ROX in human
saliva after oral intake showed that the total elimination ratio was 87.1% during 24
h, and the pharmacokinetic parameters were 0.97 ± 0.18 h<sup>-1</sup> for the
absorption rate constant <i>K<sub>a</sub></i>, 0.082 ± 0.010 h<sup>-1</sup> for the
elimination rate constant <i>K<sub>e</sub></i>, and 8.56 ± 1.11 h for the
elimination half-life time <i>t</i><sub>1/2</sub>. It was also found that ROX in
human saliva and urine simultaneously reached the maximum at 2 h with the
concentration correlate ratio of 0.97.
PDF Article
More Like This
Cited By
You do not have subscription access to this journal. Cited by links are available to subscribers only. You may subscribe either as an Optica member, or as an authorized user of your institution.
Contact your librarian or system administrator
or
Login to access Optica Member Subscription